FDA approves first treatment to reduce risk of serious heart problems in adults with obesity or overweight
Retatrutide, manufactured by Eli Lilly, is currently in phase 3 clinical trials, the step before the manufacturer can seek FDA approval, so it may be approved this year or next
Enhancing glycemic management lowers HbA1c levels and lowers the chance of consequences from diabetes, including kidney disease, nerve damage, and cardiovascular disease
Controls should mirror contemporary standard care (lifestyle metformin)
Renal and urothelial cancer risks with SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes: a target trial emulation doi.org/10.1093/ndt/gf Renal and urothelial cancer risks with SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes: a target trial emulation doi.org/10.1093/ndt/gf Join the conversation
Yes, some individuals might not see full effects due to things like insulin resistance, thyroid conditions, or gut health issues